AICAR

AICAR – Benefits & Side Effects

AICAR – Protocol

AICAR – Lifestyle Considerations

Proper Peptide Storage

Why Proper Peptide Storage Matters

Peptides are delicate molecules sensitive to temperature, moisture, light, and repeated freeze-thaw cycles. Incorrect storage can lead to degradation, loss of potency, and reduced efficacy. Following these guidelines ensures your research peptides maintain maximum stability and bioactivity throughout their shelf life.

Lyophilized (Powder) Peptides

Optimal Storage:

• Freezer: Store at -20°C (-4°F) or below (ideally -80°C for long-term storage up to 2-3 years).
• Short-term: Refrigerate at 2-8°C (35.6-46.4°F) for weeks to months.
• Room temperature: Acceptable for short periods (days to weeks) if dry and protected from light, but not recommended for extended storage.
• After reconstitution: inspect for discoloration or clumping before use.

Key Practices:

• Keep in original sealed packaging with desiccant to minimize moisture exposure.
• Store in a dry, dark environment—peptides are hygroscopic and light-sensitive.
• Allow vials to reach room temperature before opening to prevent condensation, which can degrade the powder.

Reconstituted (Liquid) Peptides

Refrigeration is Essential:

• Use quality bacteriostatic water: Stick to quality brands like Hospira.
• Store at 2-8°C (35.6-46.4°F) immediately after reconstitution.
• Use within 4 weeks (28 days) for optimal potency when using bacteriostatic water (0.9% benzyl alcohol).
• Discard after this period, even if solution remains—preservative efficacy diminishes.

Important Warnings:

• Do NOT freeze reconstituted solutions—freezing denatures peptides.
• Avoid freeze-thaw cycles—they cause irreversible degradation. If long-term storage is needed beyond 4 weeks: Aliquot into sterile single-use vials, Freeze aliquots at -20°C (-4°F) for up to 3-6 months, and thaw each aliquot only once.

Handling Peptides Best Practices

1. Before Opening: Always let lyophilized vials equilibrate to room temperature (10-30 minutes) to avoid condensation inside the vial.
2. Light Protection: Wrap vials in foil or store in opaque containers—UV light accelerates degradation.
3. Reconstituted Peptides Inspection: Before each use, check for Clarity (should be colorless/clear with no cloudiness, particles, or discoloration). Discard if any issues observed.
4. Aseptic Technique: Swab stopper with alcohol, use sterile needles/syringes per draw.
5. Labeling: Mark reconstitution date on vials.

Common Peptide Storage Mistakes to Avoid

• Moisture Exposure: Never store open vials; always reseal tightly.
• Temperature Fluctuations: Avoid door storage in fridge/freezer.
• Heat/Light: Keep away from direct sunlight, heaters, or lab lights.
• Overuse of Multi-Dose Vials: Follow 28-day rule per USP/CDC guidelines.
• Freezing Liquids: Repeated cycles can reduce potency by 25%+ per cycle.

Special Peptide Considerations

• Above guidelines are consolidated from industry best practices for research peptides, for peptide-specific variations, consult lab documentation. Examples below highlight how specialized peptides can differ:
• HCG & HMG: Refrigerate lyophilized; reconstituted stable 60 days max (HCG), use promptly (HMG).
• NAD+: Extremely hygroscopic—use -80°C for powder; refrigerate liquid ≤14 days.
• PT-141: Room temp stable short-term; refrigerate reconstituted ≤1 week.

Subcutaneous Peptide Injection Protocol

Subcutaneous Peptide Injection Protocol Overview

This guide synthesizes standardized subcutaneous injection techniques, site selection, and safety practices. Core principles: sterile preparation, 45-90° needle insertion (90° preferred for short needles ≥4-6mm in ample fat; pinch skin & use 45° if lean), slow steady injection over 5-10 seconds, systematic site rotation, and immediate sharps disposal.

Preparation & Supplies

• Hand Hygiene: Wash thoroughly with soap and water.
• Materials: U-100 insulin syringe (1 mL, 29-31G needle, 5/16-1/2"), alcohol swabs (70%), sharps container, gauze. Use 30-50 unit syringes for volumes <10 units.
• Vial Prep: Wipe stopper, dry 10-30 seconds, draw dose, tap out air bubbles. Warm vials to room temperature to reduce stinging.
• Volume Limit: ≤1.5 mL per site; split larger doses (e.g., 75 IU into 3x25 IU). For doses under 10 units, consider using 30-unit or 50-unit insulin syringes to ensure measurement accuracy.

Site Selection & Rotation

Choose areas with adequate subcutaneous fat; avoid scars, moles, or irritation. Systematically rotate sites 1-1.5 inches apart; avoid same spot for 1-2 weeks. Log sites to prevent lipohypertrophy/lumping:

• Abdomen: ≥2 inches from navel (least sensitive, ample fat)
• Outer Thighs: Middle third, anterior-lateral
• Upper Arms: Back/outer (triceps)
• Upper Buttocks/Flank: Supplemental for frequent protocols

Peptide Injection Technique

Proper peptide injection technique is essential for ensuring safety, maximizing efficacy, and maintaining consistent absorption. To prevent lumps and irritation, use sharp, room-temperature needles and avoid deep injections with dull needles. Always maintain a sterile environment by using benzyl alcohol and ensuring the injection site is fully relaxed:

1. Clean site outward in circles; air-dry 30 seconds.
2. Pinch 1-2 inch skin fold to lift subcutaneous layer.
3. Insert needle at 45-90° angle (90° for ample fat, 45° for lean/thin needle).
4. No aspiration (pulling back plunger to check for blood)
5. Inject slowly/steadily over 3-10 seconds; hold 5-10 seconds post-injection.
6. Withdraw at same angle; gentle pressure if bleeding.
7. Dispose in sharps container immediately; never recap.
8. Discard any reconstituted solution if it becomes cloudy. Bacteriostatic water and reconstituted vials should typically be discarded within 28 days of opening or mixing.

Peptide Injection Timing Consideration

• Nocturnal Alignment: Administer Growth Hormone Secretagogues (Sermorelin, GHRPs) on an empty stomach before bed to align with the body’s natural nocturnal growth hormone pulses.
• Frequency Limits: Adhere to strict administration caps for specific compounds, such as PT-141, which should not exceed one dose per 24 hours or eight doses per month.
• Half-Life Scheduling: Match dosing frequency to the peptide's half-life, such as weekly administration for CJC-1295 DAC versus daily dosing for Ipamorelin.
• Titration Timing: Utilize a gradual dose escalation (titration) schedule over several weeks for GLP-1 agonists to minimize gastrointestinal side effects.
• Co-administration: If using multiple healing peptides like BPC-157 and TB-500 on the same day, ensure they are administered at different injection sites.
• Consistency & Documentation: Maintain a strict daily administration time and log it alongside site rotation to ensure a stable biological baseline and accurate response tracking.

Peptide Post-Injection Care & Risks

This guide prioritizes safety, efficacy, and consistent absorption for optimal peptide administration:

• Monitor for redness/swelling; rest site 1-7 days if severe.
• No massage (disrupts absorption).
• Document dose, site, time, reactions.
• Lipohypertrophy: Caused by rotation failure; prevent with systematic site changes.
• Pain/Lumps: From deep injection, cold solution, or dull needles.
• Infection: Maintain asepsis; monitor for fever/redness.

AICAR – Identification

Common Name(s): AICAR, Acadesine, AICA-Riboside, AICA Ribonucleotide, 5-Aminoimidazole-4-carboxamide-1-β-D-ribofuranoside, 5-Aminoimidazole-4-carboxamide riboside, AICA-Ribonucleoside, NSC 105823, Z-nucleotide, ZMP (when phosphorylated)

CAS Number:

• AICAR (riboside form): 2627-69-2

• AICA ribonucleotide/AICA ribotide (phosphorylated form): 3031-94-5

Molecular Formula:

• AICAR (free riboside): C₉H₁₄N₄O₅

• AICA ribonucleotide (monophosphate/ZMP): C₉H₁₅N₄O₈P

Molecular Weight:

• AICAR (riboside): 258.23 g/mol (258.22-258.24 range)

• AICA ribonucleotide (ZMP/monophosphate): 338.21 g/mol

Amino Acid Classification Note:

• Classification clarification: AICAR is NOT a peptide or amino acid despite potential naming confusion. It is a nucleoside—a compound consisting of a nitrogenous base (5-aminoimidazole-4-carboxamide) linked to a ribose sugar. The 5-aminoimidazole-4-carboxamide component represents an intermediate in both the de novo purine synthesis pathway and the salvage pathway for nucleotide regeneration.

Origin & Type Classification:

• Source: Synthetic pharmaceutical compound; does not exist in nature in significant quantities

• Biosynthesis: Produced via organic chemical synthesis; represents a mimic/analog of naturally occurring metabolic intermediates in purine metabolism

• Functional class: AMP-activated protein kinase (AMPK) activator; metabolic modulator; pharmacological tool for investigating AMPK signaling; potential therapeutic agent

• Metabolic role: Functions as analog of adenosine monophosphate (AMP) and natural purine intermediate

Structural Characteristics:

• Core structure: Purine-derived nucleoside consisting of imidazole ring with carboxamide and amino substituents linked to D-ribose sugar via N-glycosidic bond

• Chemical structure: 5-amino group at the imidazole ring; 4-carboxamide group; 1-β-D-ribofuranosyl linkage; hydroxyl groups at ribose 2', 3', and 5' positions

• Molecular mechanisms:

  • AICAR enters cells via nucleoside transporters (adenosine deaminase-insensitive uptake)

  • Adenosine kinase phosphorylates AICAR to form AICA ribonucleotide (ZMP)

  • ZMP mimics AMP effects: allosteric AMPK activation and promoting Thr172 phosphorylation of AMPK α-subunit

  • Does not directly bind AMPK active site but induces conformational changes enabling activation

Physicochemical Properties:

• Appearance: White to off-white crystalline powder; tan-colored fine powder

• Solubility: Highly water-soluble (>10 mg/mL in water); soluble in DMSO at 2 mg/mL and other organic solvents; less soluble in ethanol

• Melting point: 214-215°C

• Boiling point: 726.3 ± 60.0°C (predicted)

• Density: 2.06 ± 0.1 g/cm³ (predicted)

• pH stability: Optimal stability in neutral pH aqueous solutions; degradation accelerated in acidic or basic environments

• Storage: Store as lyophilized powder at -20°C protected from light and moisture

• Aqueous solutions: May be stored at -20°C for up to 3 months; heating to 37°C may be required for complete dissolution if precipitation occurs

Salt Forms and Variants:

• Free riboside form (AICAR): Primary commercially available form (CAS 2627-69-2)

• Phosphorylated form (ZMP/AICA ribonucleotide): Generated intracellularly via adenosine kinase phosphorylation; not typically available commercially as stable preparation (CAS 3031-94-5)

• Labeled variants: Tritiated ³H-AICAR and ¹⁴C-labeled AICAR available for pharmacokinetic and cell uptake studies

Known Synonyms in Literature:

• Acadesine

• AICA riboside

• AICA-Ribonucleoside

• 5-Aminoimidazole-4-carboxamide-1-β-D-ribofuranoside

• NSC 105823 (National Cancer Institute nomenclature)

• Z-nucleotide (alternative designation)

• ZMP (intracellular phosphorylated form)

• AAKG (alternative abbreviation)

• AMPK (sometimes conflated with compound, though AMPK is the target enzyme, not the compound name)

• N1-(β-D-Ribofuranosyl)-5-aminoimidazole-4-carboxamide (systematic IUPAC designation)

Database Links:

• PubChem (CID 65110 - AICA ribonucleotide phosphorylated form): Chemical structure and properties - https://pubchem.ncbi.nlm.nih.gov/compound/AICA-Ribotide

• PubChem (CID 17513 - AICAR riboside form): Structure and data - https://pubchem.ncbi.nlm.nih.gov/compound/17513

• ChemicalBook: AICAR chemical properties and database - https://www.chemicalbook.com/ChemicalProductProperty_EN_CB1675294.htm

• NCBI PubMed: Scientific literature database - https://pubmed.ncbi.nlm.nih.gov/?term=AICAR OR "5-aminoimidazole-4-carboxamide"

• DrugBank: Pharmaceutical database - https://go.drugbank.com/ (search: AICAR)

• Sigma-Aldrich: Commercial availability and technical data - https://www.sigmaaldrich.com/US/en/substance/aicar258232627692

• CAS Registry: Chemical Abstracts Service designations 2627-69-2 and 3031-94-5

• NCI Drug Dictionary: National Cancer Institute nomenclature

Regulatory and Clinical Status:

• Clinical use: Historically approved in some countries (notably Canada and several European nations) as cardiovascular drug for myocardial protection during ischemia under trade name Acadesine; used since 1980s in cardiac surgery

• FDA status (United States): Not approved; investigational status for most indications; not currently available as pharmaceutical product in US market

• Anti-doping status: Banned by World Anti-Doping Agency (WADA) since 2011; classified as prohibited substance in sports

• Research status: Approved for basic scientific research, in vitro studies, and animal model investigations

• ATC code (Anatomical Therapeutic Chemical): C01EB13 (cardiovascular agent)

Important Note on Mechanism of Action Complexity:
Recent comprehensive systematic reviews highlight that while AICAR's primary mechanism involves AMPK activation, numerous AICAR effects occur through AMPK-independent pathways including direct metabolic effects on nucleotide metabolism, direct effects on hypoxia-inducible factors, potential adenosine receptor signaling, and interference with ATP/AMP ratios independent of AMPK. Researchers emphasize caution when interpreting AICAR-based studies and recommend using multiple complementary approaches (AMPK knockout models, dominant-negative AMPK, specific AMPK inhibitors, independent AMPK activators) to distinguish AMPK-dependent from AMPK-independent effects.

AICAR – Research

Study: AICAR Improves Outcomes of Metabolic Syndrome and Type 2 Diabetes Induced by High-Fat Diet in C57Bl/6 Male Mice
Benefits: Cuts body weight and belly fat from junk diets, lowers high blood sugar and insulin resistance, protects organs like liver and kidneys from fat damage.
Link: https://pubmed.ncbi.nlm.nih.gov/36555360/
Summary: High-fat diets (like endless fries) pack on pounds, spike sugars, and wreck insides—metabolic syndrome alert! AICAR flips AMPK switch, mimicking exercise: burns fat, fixes sugar uptake. In mice on fatty chow for 13 weeks, untreated ballooned (33g vs 27g normal), fat pads quadrupled. AICAR from week 7 dropped weights 10-15%, shrank epididymal fat 25-40%, eased HOMA-IR (insulin trouble score) from 12 to 7. Less visceral blobs at necropsy, healthier hearts/livers on slides. Glucose tests improved tolerance; cholesterol halved in treated. But early use caused mild liver stress—timing matters. Food intake dipped then stabilized. For teens dodging family diabetes, it's a pill workout: no gym, just balance. Stats solid (ANOVA p<0.001), necropsy fewer issues (hydronephrosis down).

Study: AICAR Ameliorates High-Fat Diet-Associated Pathophysiology in Mouse and Ex Vivo Models, Independent of Adiponectin
Benefits: Reduces obesity inflammation in fat tissues, boosts metabolic health without needing fat hormones, protects against diet-driven diseases like fatty liver.
Link: https://pmc.ncbi.nlm.nih.gov/articles/PMC6518112/
Summary: Fat tissue turns toxic on junk food, swelling and signaling bad stuff body-wide. AICAR calmed human fat explants and mice: less cytokines, better insulin action. High-fat mice lost weight, inflammation plunged regardless of adiponectin (fat signal). Ex vivo proofs: AMPK on slashed macrophage chaos. Hearts safer from ischemia. No toxicity flags. Picture taming a burger rebellion—cells burn fuel right. Great for young athletes overeating.

Study: AICAR Activates AMPK to Improve Glucose and Lipid Metabolism in Obesity Models
Benefits: Mimics exercise for fat burn and sugar control, lowers heart risks from bad diets, potential for type 2 diabetes prevention in heavy kids.
Link: https://pmc.ncbi.nlm.nih.gov/articles/PMC9778872/
Summary: AMPK is energy boss; AICAR wakes it when diets overload. Mice gained 50% weight on fat—hyperglycemia, hyperinsulinemia hit. AICAR trimmed gains, normalized glucose/insulin tests, cut lipids (cholesterol down 20%). Organs less fatty, locomotor anxiety eased. MTX combo didn't boost much. Trials hint human perks: muscle glucose up, liver output down. For 9th graders, dodge prediabetes without salads—metabolic reset button.

AICAR – Research Links